At a glance
- Originator Pfizer
- Class Antirheumatics
- Mechanism of Action Tumour necrosis factor inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 21 Mar 2000 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)
- 20 Feb 1997 Preclinical development for Rheumatoid arthritis in USA (Unknown route)